Sartorius AGSARTF 85 EPS without NRI is $3.80 as of Mar. 2026. GuruFocus rates SARTF with a GF Score™ of 85/100 and a GF Value™ of $234.29 (Modestly Undervalued). The stock has 9 warning signs investors should review. Among 667 Medical Devices & Instruments companies, Sartorius AG ranks worse than 90.55% on this metric.
Sartorius AG's earnings per share without non-recurring items for the
three
months ended in Mar. 2026 was $0.94.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was $3.80.
During the past 12 months, Sartorius AG's average earnings per share (NRI) Growth Rate was 72.20% per year.
During the past 3 years, the average earnings per share (NRI) Growth Rate was -33.30% per year.
During the past 5 years, the average earnings per share (NRI) Growth Rate was -18.00% per year.
During the past 10 years, the average earnings per share (NRI) Growth Rate was 7.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Sartorius AG's EPS without NRI or its related term are showing as below:
SARTF'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -35.9 Med: 20 Max: 92
Current: -33.3
During the past 13 years, Sartorius AG's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 92.00% per year. The lowest was -35.90% per year. And the median was 20.00% per year.
SARTF's 3-Year EPS without NRI Growth Rate is ranked worse than 90.55% of 667
companies
in the Medical Devices & Instruments industry
Industry Median: 8.1
vs SARTF: -33.30
Sartorius AG's EPS (Diluted) for the
three
months ended in Mar. 2026 was $0.94.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $3.80.
Sartorius AG's EPS (Basic) for the
three
months ended in Mar. 2026 was $0.94.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $3.80.
Sartorius AG (OTCPK:SARTF) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Sartorius AG EPS without NRI Related Terms
Sartorius AG EPS without NRI Historical Data
* Premium members only.
The historical data trend for Sartorius AG's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SARTF vs ISRG, BDX, MDLN: EPS without NRI Comparison
For the Medical Instruments & Supplies subindustry, Sartorius AG's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sartorius AG PE Ratio without NRI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sartorius AG's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Sartorius AG's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.80
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sartorius AG (SARTF) has a EPS without NRI of $3.80 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Sartorius AG and its competitors. According to the industry distribution chart, Sartorius AG ranks #604 out of 667 companies in the Medical Devices & Instruments industry, placing it in the top 90.6%.
Is Sartorius AG's EPS without NRI too high?
Sartorius AG's current EPS without NRI is $3.80. The Medical Devices & Instruments industry median EPS without NRI is 8.10. Sartorius AG's value of $3.80 is 53.1% below this industry median. Based on the distribution chart, Sartorius AG ranks #604 out of 667 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Sartorius AG has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius AG's EPS without NRI compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sartorius AG ranks #604 out of 667 companies for EPS without NRI. This places Sartorius AG in the lower half of its industry. The industry median EPS without NRI is 8.10. Sartorius AG's value of $3.80 is 53.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Medical Devices & Instruments company?
The median EPS without NRI among Medical Devices & Instruments companies is 8.10, based on 667 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sartorius AG's current EPS without NRI of $3.80 is 53.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Sartorius AG and its competitors. For the Medical Devices & Instruments industry, the median EPS without NRI is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sartorius AG's current EPS without NRI is $3.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius AG stock overvalued right now?
Based on GuruFocus' analysis, Sartorius AG (SARTF) is currently considered Modestly Undervalued. The stock's GF Value™ is $234.29, compared to a current price of $212.80 — trading 9.2% below its estimated fair value. The current EPS without NRI is $3.80 and 53.1% below the Medical Devices & Instruments industry median of 8.10. Sartorius AG's overall GF Score™ is 85/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Sartorius AG (SARTF), the current EPS without NRI is $3.80 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius AG (SARTF) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius AG stock appears to be undervalued.
The current stock price of $212.80 is trading 9.2% below its estimated GF Value™ of $234.29.
GuruFocus considers Sartorius AG to be Modestly Undervalued.
Key valuation signals for SARTF:
EPS without NRI: $3.80
GF Value™: $234.29 vs. price of $212.80 (9.2% below fair value)
Industry Position: 53.1% below the Medical Devices & Instruments median (#604 of 667)
No single metric tells the full story. See the SARTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs and focuses on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
85GF Score
Get the complete analysis for SARTF
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SARTF has been successfully added to your 
